Jupiter Neurosciences Launches Nugevia鈩�: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
- Launch of revenue-generating consumer product line in Q3 2025 creates near-term income potential
- Products leverage clinically-proven JOTROL technology with 9x improved bioavailability
- Strategic entry into $8 trillion longevity market by 2030
- Revenue from consumer products can help fund ongoing clinical trials
- Entering competitive consumer supplement market with no prior commercial experience
- Potential distraction from core pharmaceutical development business
- Success depends on consumer adoption of premium-priced supplements
Insights
Jupiter's launch of Nugevia supplements creates diversified revenue stream while leveraging existing clinical technology in the booming longevity market.
Jupiter Neurosciences' strategic pivot into the consumer health space with Nugevia represents a significant business model expansion that could transform their financial outlook. By commercializing their proprietary JOTROL鈩� technology platform in the consumer market, Jupiter is creating a dual-revenue approach that addresses both short and long-term growth horizons鈥攕omething rarely executed successfully in biotech.
The company's approach shows remarkable capital efficiency by leveraging the same technology across both clinical and consumer applications. Their JOTROL鈩� delivery system, which demonstrated 9x improved bioavailability in clinical trials, provides a genuine competitive advantage in the oversaturated supplement market where efficacy claims often lack substantiation. This scientific differentiation could command premium pricing and higher margins.
Timing is particularly strategic as Jupiter enters the longevity market projected to reach
The direct-to-consumer model also allows Jupiter to capture higher margins than traditional retail distribution would permit, while their "intelligent stacking" approach of synergistic compounds creates potential for product differentiation and intellectual property protection beyond their core JOTROL鈩� technology.
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (鈥淛upiter鈥� or the 鈥淐ompany鈥�), a clinical-stage pharmaceutical company developing JOTROL鈩�, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia鈩�, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter鈥檚 strategy to generate near-term revenue while maintaining momentum in its clinical pipeline.
Nugevia鈥檚 debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter鈥檚 proprietary JOTROL鈩� micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space.
鈥淭he launch of Nugevia is the natural next step in translating our science into broad, real-world impact,鈥� said Christer Ros茅n, Chairman and CEO of Jupiter Neurosciences. 鈥淏y building on the same proprietary technology platform that underpins our prescription drug development, we鈥檙e delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.鈥�
A New Standard in Evidence-Based Supplementation
Nugevia鈥檚 first three formulations鈥攖argeting mitochondrial support, mental clarity, and "beauty from within"鈥攚ill be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL鈩�, Jupiter鈥檚 enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL鈩� is also the foundation of Jupiter鈥檚 ongoing therapeutic programs in Parkinson鈥檚 and Alzheimer鈥檚 disease.
Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization.
鈥淲e cracked the code on resveratrol鈥檚 widely published issue with bioavailability, and now we鈥檙e unlocking its potential beyond the clinic,鈥� added Ros茅n. 鈥淐onsumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.鈥�
Strategic Synergy with Core Pipeline
The Nugevia launch adds a new dimension to Jupiter鈥檚 value proposition as a dual-path company鈥攁dvancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach
The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model.
鈥淣ugevia represents more than a product launch鈥攊t鈥檚 a strategic engine for growth,鈥� said Ros茅n. 鈥淏y leveraging our core science in a consumer format, we鈥檙e creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It鈥檚 smart capital allocation with real scientific impact.鈥�
A digital press kit, including high-resolution product imagery and key brand information, is available at .
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company鈥檚 platform product, JOTROL鈩�, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company鈥檚 pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer鈥檚 Disease, Parkinson鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
About JOTROL
Resveratrol is one of the world鈥檚 most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer鈥檚 Disease trial, and Yui et al., Friedreich鈥檚 Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer鈥檚 Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson鈥檚 Disease.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
FAQ
When will Jupiter Neurosciences (JUNS) launch its Nugevia supplement line?
What products will be included in Jupiter Neurosciences' Nugevia launch?
What is the competitive advantage of JUNS's Nugevia supplements?
How does Nugevia fit into Jupiter Neurosciences' business strategy?
What is the market potential for Jupiter's Nugevia product line?
